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A B S T R A C T
Despite major advances in osteoporosis diagnosis and treatment, low rates of investigating and treating osteo-
porosis in patients with fragility fracture are reported in Pakistan. Cost of therapies, time and cost of resources
for diagnosis, concerns about medications and lack of clarity regarding the onus of responsibility to undertake
this care, are some of the barriers to osteoporosis identification and treatment. Data from our part of the world
on osteoporosis as well as on fragility fractures is sparse. This review addresses the current screening and di-
agnostic strategies for osteoporosis and reviews the existing literature to highlight the issues prevalent in our
society on this major public health problem.
1. Introduction
National Institute of Health (NIH) consensus development panel
defines osteoporosis as a systemic skeletal disorder characterized by
compromised bone strength predisposing to an increased risk of frac-
ture, where bone strength is reflected by integration of bone density
and bone quality [1]. Osteoporotic fractures or fragility fractures are
low trauma fractures occurring with a force equal to or less than falling
from standing height. This definition arises because a normal human
being ought to be able to fall from standing height without breaking
any bones, and a fracture therefore suggests weakness of the skeleton.
Pain and disability are the potential outcomes. Quality of life is affected
with dependence on others [2] [3].
Despite major advances in osteoporosis diagnosis and treatment,
low rates of investigating and treating osteoporosis in patients with
fragility fracture have been reported internationally [4–7]. Practicing
patterns in the diagnosis and treatment of osteoporosis after a fragility
fracture [8],have shown that patients with fragility fractures are usually
not always investigated or treated for the underlying osteoporosis. The
rate of investigation of osteoporosis by bone densitometry has also been
low. Even in the studies that reported high rates of osteoporosis diag-
nosis (35–100%), there was only moderate use of pharmacological and
life style intervention. Studies on barriers to osteoporosis identification
and treatment identifies cost of therapies, time and cost of resources for
diagnosis, concerns about medications and lack of clarity regarding the
responsibility to undertake this care, as some of the issues [8,9].
Data from our part of the world on osteoporosis as well as on
fragility fracture is sparse. Even in developed countries where osteo-
porosis is widely recognized, the practicing pattern of physicians in
screening, diagnosing and then treating fragility fractures with focus on
osteoporosis needs a lot to be done [8,10,11]. This review addresses the
current screening and diagnostic strategies for osteoporosis and reviews
the existing literature to highlight the issues prevalent in our society on
this significant public health problem.
2. Methodology
Articles from Google scholar were selected by using the search terms
“Osteoporosis”, “osteopenia”, “fracture risk assessment”, “fragility
fracture”, “risk factors for osteoporosis”, “bone turn over markers”,
“vitamin D” and “bone health” in “Pakistan”. Inclusion criteria were
articles published in English in peer-reviewed journals, from Pakistan
ranging from 1990 to 2017. The articles were further filtered in a team
meeting, keeping in view the ideology behind this narrative review, i.e.,
current screening and diagnostic strategies for osteoporosis and review
of the existing literature to highlight the issues prevalent in our society
on this major public health problem.
2.1. Osteoporotic fracture risk assessment
Clinical history, physical examination and routine x-rays diagnose
osteoporosis in its advanced stages. Occurrence of first fracture in a
previously asymptomatic individual is often the first indication for the
presence of osteoporosis. First fracture is a major risk factor for
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subsequent fractures and therefore the ultimate goal is to diagnose
osteoporosis even before first fracture occurs. The value of bone den-
sitometry in the management of individual patients is as a measure of
risk and not as either or diagnostic criterion. Low bone mineral density
(BMD) cannot always translate into enhanced fracture risk. Information
on bone mass should be added to information on clinical risk factors
and non-skeletal risk factors like potential to fall should be balanced
against the benefits and risks of the intervention considered.
A number of BMD-independent risk factors for insufficiency frac-
tures are now recognized. It is important to differentiate risk factors for
low bone mass from risk factors for fracture and risk factors for falling
(Table 1). None of the risk factors predict bone mass with sufficient
accuracy in an individual patient. The best combination of risk factors
accounts for 20% variability in bone mass and provide information
about the risk of osteoporosis. They are used to target individuals for
further investigations (BMD and bone turnover marker) and treatment.
They also provide an opportunity to discuss with the patient those
factors (life style and secondary causes of osteoporosis) that can be
eliminated or altered.
The limited accuracy of BMD alone to predict fractures has led to
the development of fracture risk assessment tools that utilize the
combination of bone density and clinical risk factors to improve frac-
ture risk prediction. The fracture risk assessment tools qualitatively
predict the 10-year fracture probability of hip and major osteoporosis
related fractures and can be used to define cost effective intervention
strategies for primary and secondary fracture prevention. Available
major osteoporosis screening instruments and algorithms include WHO
Fracture Risk Assessment Tool (FRAX), the Garvan Institute fracture
risk calculator (Garvan) and QfractureScores (Qfracture), simple cal-
culated osteoporosis risk estimation (SCORE), Age, BOdy size, No
Estrogen (ABONE), OSteoporosis Index of RISk (OSIRIS), Study of
Osteoporosis Fractures-Study Utilizing Risk Factors (SOFSURF), osteo-
porosis self-assessment tool (OST), National Osteoporosis Foundation
(NOF) guidelines, Weight-Only–EPIDOS (WO-E) and Osteoporosis Risk
Assessment Instrument (ORAI) [12–25]. Most of these are based on
non-Asian populations. Unfortunately no such tool is available for Pa-
kistan where the risk factors are different from the Caucasians. Osteo-
porosis screening questionnaires have thus far not been validated in
Pakistani community.
2.2. Value of bone mineral density
The definition of osteoporosis developed for World Health
Organization (WHO) is based on bone densitometry. Normal bone mass
is defined as BMD above or below 1 standard deviation (SD) from the
premenopausal mean value (T-score), osteopenia as BMD below -1SD
but above−2.5 SD and osteoporosis is as BMD below−2.5SD [26,27].
These definitions are used to provide diagnostic labels, but not ne-
cessarily indications for intervention.
It is useful for fracture risk assessment as BMD is correlated with
bone; for each SD decrease in BMD there is an approximately two fold
increase in risk of fracture, depending on site of measurement and the
technique used [28]. Quantitative assessment of bone mass by DXA
allows serial monitoring of patients. In untreated patients, significant
loss may be an indication for treatment and is associated with an in-
creased fracture risk. In treated patients, DXA is used to monitor re-
sponse to therapy. An increase in BMD or stable BMD is encouraging
and is associated with fracture risk reduction. Further evaluation is
considered for those who are losing BMD. The National Osteoporosis
Foundation (NOF), American College of Obstetricians and Gynecolo-
gists and International Society for Clinical Densitometry (ISCD) re-
commend BMD testing for women ≥65 years of age and for younger
women with high risk of fracture [29]. Monitoring for treatment effects
is recommended 1–2 years after starting or changing therapy, with
consideration of longer testing intervals once a favorable treatment
effect is confirmed. Table 2 shows the indications for BMD testing as per
ISCD recommendations. The ISCD official position states that intervals
between BMD testing should be determined according to each patient's
clinical status.
2.3. Value of bone turnover markers
High bone turnover as estimated by biochemical markers is asso-
ciated with an increased rate of bone loss, and predicts the risk of
fracture independently of BMD [30–32]. Markers of bone turnover can
be allocated into two groups: markers of resorption and markers of
formation. The primary markers of bone formation are total alkaline
phosphatase, the bone isoenzyme alkaline phosphatase, osteocalcin,
and the procollagen propeptides of type I collagen. The odds ratio for
hip fracture seems to be increased around 2 fold in those with normal
BMD but bone turnover biochemical marker above the premenopausal
range [33]. Several assays are currently available that measure bone
turnover markers. These assays measure collagen breakdown products
and other molecules in blood and urine released from osteoclasts and
Table 1
Clinical evaluation of bone health based on risk factors.
Risk factors for low bone mass Risk factors for fall Risk factors for
fracture
Intrinsic Causes
Age (x2 risk/decade)
Female gender
Caucasian or Asian ethnicity
Thin body build (body mass
index< 20)
Previous fragility fracture
(x10 risk of future fracture)
Low trauma fracture in first
degree relative
Endocrine Causes
Premature menopause
(< 45 years) – natural or
surgical
Previous amenorrhea (> 6
months duration)
Cushing's syndrome
Hyperparathyroidism
(primary or secondary)
Hypogonadism
Thyrotoxicosis
Gastrointestinal and
nutritional factors
Life style
Low level of physical
activity
Poor calcium intake
(< 0.5 g/d)
Alcohol excess (> 14 units/
week)
Cigarette smoking
Fragility fracture
Reduced Vision
Orthostatic
hypertension
Pain
Impaired ambulation
and/or balance
Muscle weakness
Depression
Long term disability
Living alone
Use of drugs:
sedatives, diuretic or
anti-arrhythmic
Foot problems
(bunions, toe
deformities, ulcers,
deformed nails)
Improper use of
assistive device
Extrinsic factors:
Lack of stair
handrails, Lack of
bathroom grab bars,
Dim lighting
Low bone mineral
density
Advancing age
Prior fracture
Family history of
osteoporosis or
fragility fracture in a
first degree relative
Current smoker
Low body weight
Falls
Sarcopenia
Dementia
Chronic illnesses
Use of corticosteroids
Table 2
Indications for bone mineral density (BMD) testing.
Women aged 65 and older
Post-menopausal women under age 65 with risk factors for fracture
Women during the menopausal transition with clinical risk factors for fracture, such
as low body weight, prior fracture, or high risk medication use
Men aged 70 years or older
Men under age 70 with clinical risk factors for fracture
Adults with a fragility fracture
Adults with a disease or condition associated with low bone mass or bone loss
Adults taking medicine associated with low bone mass or bone loss
Anyone being considered for pharmacologic therapy
Anyone being treated, to monitor treatment effect
Anyone not receiving therapy in whom evidence of bone loss would lead to treatment
A.H. Khan et al. Annals of Medicine and Surgery 29 (2018) 19–25
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osteoblasts during the process of bone resorption and formation. If bone
turnover markers are used to monitor osteoporosis therapy baseline and
post-treatment serum/urine samples should be obtained under stan-
dardized conditions and analysis should be performed from same la-
boratory.
2.4. Screening for secondary causes of osteoporosis
Certain medical conditions and medications completely unrelated to
osteoporosis can nevertheless have the effect of causing osteoporosis. In
patients with symptomatic vertebral fractures, secondary causes of os-
teoporosis should be identified by careful history, physical examination
and appropriate investigation. Underlying secondary causes of osteo-
porosis should also be sought in men and women presenting with low
trauma hip and other non-vertebral fractures. Tests to exclude sec-
ondary causes of osteoporosis include complete blood count, ery-
throcyte sedimentation rate, serum calcium, phosphate, vitamin D,
parathyroid hormone, liver and kidney function tests, serum thyroid
stimulating hormone and 24-h urinary calcium levels. Routine bio-
chemical profile is probably worthwhile, as hypocalcaemia & hypo-
phosphatemia may indicate possible osteomalacia. In a multinational
cohort study (GLOW) by Dennison et al., in 2012, it is shown that co-
morbidities contributed significantly to fracture risk and suggested
greater awareness of the relationship between co-morbidities and
fracture risk in improving fracture-prediction algorithm [34].
2.5. Treatment goals for prevention and treatment of osteoporosis
The treatment goals in the first place include decreasing the fracture
risk by stabilizing or increasing bone mass and maintaining or im-
proving bone quality and strength. Therapy is targeted to pathophy-
siological risk factors for fractures such as calcium/vitamin D deficiency
and factors such as estrogen deficiency that cause loss of bone mineral.
Patients with osteoporosis are also at risk for fracture because of a
tendency to fall; most fractures are the result of a fall onto a fragile
bone. Observational studies show that low levels of physical activity
and poor muscle strength are risk factors for future fracture, and ran-
domized trials show that exercise will improve muscle strength and
reduce the risk of falling [35,36].
There are three components to the non-drug treatment of osteo-
porosis: diet, exercise, and cessation of smoking. The universal re-
commendations for improvement of bone health from NOF include
adequate intake of dietary calcium and vitamin D, regular weight
bearing and muscle strengthening exercises, avoidance of smoking and
excess alcohol and fall prevention in elderly. Many studies suggest that
calcium and vitamin D supplementation decreases the risk of fractures.
The incidence of non-vertebral fractures in 3270 ambulatory elderly
women who were randomized to receive either 1200mg of calcium and
800 IU of vitamin D or placebo; incidence of hip fractures and all non-
vertebral fractures was significantly lower in the supplemented group
[37]. In a different study of 389 adults age>65, who were randomized
to receive either 500mg of calcium or 700 units of VD daily or placebo.
Treatment was associated with an improvement in BMD and a decrease
in incidence of all non-vertebral fractures [38]. While not all rando-
mized trials agree that treatment with calcium and vitamin D will re-
duce the risk of fractures, there are enough data to suggest safety and
efficacy to recommend 800 Units of vitamin D and 1200mg of calcium
daily. Though the changes in BMD that occur with treatment with
calcium and vitamin D are small, but still resulted in a substantial and
significant reduction in fracture risk. There is therefore speculation that
treatment with calcium and vitamin D reduce the incidence of fractures
by other means as well like reducing falls.
There are many things to think about when choosing the right os-
teoporosis treatment option such as gender, age, the severity of osteo-
porosis and patient's personal preference. The drugs approved for os-
teoporosis treatment include bisphosphonates, calcitonin, selective
estrogen receptor modulators, parathyroid hormone and RANK ligand
inhibitors. Drugs approved for treatment of osteoporosis have been
proven in randomized clinical trials to improve BMD and decrease the
rate of non-vertebral fractures compared to calcium and vitamin D
alone. Data from different trials are not directly comparable, because
the clinical trials differed in number and types of patients enrolled [39].
3. Osteoporosis in Pakistan
3.1. Prevalence of osteoporosis
Due to lack of national registries and lack of published data there is
a paucity of epidemiological data on osteoporosis in Pakistan. The di-
agnostic facilities of osteoporosis are meagre and there are limited
numbers of DXA machines available only in large towns and cities. In
last 5 years, several hospital based studies have shown prevalence of
osteoporosis using heel ultra sound and the data on BMD using DXA is
scarce. Table 3 summarizes studies done on bone health on Pakistani
population in the last decade. Available evidence suggests that the
burden of osteoporosis is high in this part of the world ranging from 5.6
to 17.8% in pre-menopausal females and 20–49.3% in postmenopausal
females. A study conducted in Peshawar on postmenopausal women
(n= 1000) for simple calculated osteoporosis risk estimation, found
that 75.3% were predisposed to osteoporosis and the risk increased
with age (97% in women of 75–84 years of age compared to 55% in
women of 45–54 years of age) [40]. Accurate data on osteoporosis
prevalence is lacking and all these studies have used heel ultrasound
and not DXA as their research tool. Almost all the studies have been
reported from urban areas of the country. There are the concerns that
the estimation of osteoporosis burden using available published data
underestimates the number of people with the disease.
3.2. Status of knowledge about osteoporosis
There is generally a low level of osteoporosis awareness in the
country. Though there have been individual efforts, but no government
policy and osteoporosis is still not recognized as a major health issue in
Pakistan. The low awareness levels is linked to low level of education,
infrequent contact with the health service, large family size and poor
economic conditions. In addition, people are not aware of importance
of calcium intake in peri-menopausal period [41]. A study on healthy
females attending a tertiary care hospital reported that Pakistani
women from higher socioeconomic status had significantly better
knowledge about osteoporosis than women of lower socioeconomic
status but this knowledge did not improve life style/preventive habits
for osteoporosis [42]. A study from a tertiary care hospital showed low
rates of calcium and vitamin D supplementation for patients discharged
after surgery for hip insufficiency fractures [43].
3.3. Osteoporosis risk factors in Pakistan
There is a scarcity of solid epidemiological data on osteoporosis in
Pakistan but the osteoporosis risk factors, multi-parity, increased post-
menopausal years, decreased calcium intake, vitamin D deficiency and
lack of physical activity are on the rise [44,45]. Risk factors included
from research work from Peshawar included age of menopause and
menarche, pregnancies, children, history of personal fracture and of
siblings, history of smoking, drugs, occupation and income while the
mean calcium intake in these 140 postmenopausal females was sig-
nificantly lower than the World Health Organization's dietary re-
commended intake of 1300mg/day [46].
Significant osteoporosis risk factors found in 103 post-menopausal
females having hip fracture; were early menopause, longer duration of
menopause, low BMI, poor socioeconomic conditions, multi-parity,
smoking, illiteracy, lack of calcium supplements, injudicious use of
steroids and poor visual acuity. The mean age of the study group was
A.H. Khan et al. Annals of Medicine and Surgery 29 (2018) 19–25
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64.6 years and average duration of menopause was 9.9 years and the
study also reported that 70.9% women did not exercise [47].
3.4. Bone turnover
Although relatively little is known about the osteoporosis risk fac-
tors in Indian & Pakistani, osteoporotic fractures usually occur 10–20
years earlier in Indian men and women compared with their western
counterparts. In a cross sectional study the relative contributions of
ethnicity, reproductive history, body size and composition, bone turn-
over, serum 25 OHD, dietary intake of calcium, fiber & alcohol & energy
expenditure to femoral BMD & hip axis length were studied in Indians/
Pakistanis and Caucasians. Findings revealed that Indian/Pakistani
women had lower BMD than their American counterparts, placing them
at greater risk of fracture. Shorter hip axis length of the Indian/
Pakistani vs American Caucasians might attenuate hip fracture risk in
the former group. Some of the significant contributors to proximal
femur BMD were calcium intake and usual alcohol intake. Although
serum 25OHD & urinary NTx concentration did not contribute to fe-
moral BMD in the regression models, the lower serum 25OHD & higher
NTx values in Indian Pakistani versus American Caucasian, respectively
coupled with their lower BMD, places them at higher risk of osteo-
porosis. In one of our studies to assess bone health in healthy females,
high bone turnover was seen with vitamin D deficiency and secondary
hyperparathyroidism.
3.5. Vitamin D status
The two main determinants of bone health are calcium and vitamin
D. Recently, studies from different cities of Pakistan has shown very
high prevalence of vitamin D deficiency and insufficiency in randomly
selected healthy and patient population (Table 4). According to the
‘National Nutrition Survey 2011’ of Pakistan, 66.2% of the non-preg-
nant and 68.5% of the pregnant mothers were found D deficient [48].
Despite ample sunshine, Pakistan has the highest rates of vitamin D
deficiency worldwide. In a recent study to assess bone health in healthy
adult population high bone turnover was seen in healthy pre-
menopausal community females [49].
Consistent predictors of low levels of 25OHD are duration of sun
exposure and practice of wearing veil. Entire need for vitamin D can be
met by adequate exposure to sunlight. Exposure of arms & legs for
5–30min (depending on time of day, season, latitude & skin pigmen-
tation) between 10am and 3pm twice a week is often adequate. In the
absence of adequate sun exposure the body depends on dietary supply
for vitamin D. Unlike many Western countries that have a vitamin D
food fortification policy, Pakistan does not have a mandatory vitamin D
fortification policy in place. With longer exposure to UVB rays, an
equilibrium is achieved in the skin, and the vitamin simply degrades as
fast as it is generated.
International recommendations and guidelines regarding desirable
doses and levels may not readily apply to population from our region.
On the other hand the calcium intake is assessed to be low based on
food frequency questionnaire.
3.6. Fractures
Despite the high prevalence of osteoporosis and osteopenia in
Pakistan, there is not enough information regarding the prevalence of
osteoporosis-related fractures and the burden of the diseases. Published
data on incidence rates for hip fractures is not available.
Mortality rates post hip fractures are not known from this region.
While such rates vary between 25 and 35% in western population, they
are 2–3 folds higher in Middle East. Information on social costs and
quality of life is practically non-existent.
3.7. Life style variables
According to The National Osteoporosis Foundation, lifestyle
adoptions effect 20–40% of adult bone mass. Therefore, modification of
lifestyle factors is a key strategy intended at reducing risk of osteo-
porosis in advanced age.
A recently published community based study from our center done
on females showed that the significant predictors of vitamin D defi-
ciency were aging, housing structure and town of residence [50].
4. Conclusion
Economic development has resulted in rapid socioeconomic
changes. Non-communicable diseases have become the leading cause of
mortality and morbidity. It is important that concerned stakeholders
should establish a priority list of objectives and a time table for a plan of
action to develop appropriate programs and advocate for policy change,
to render the diagnosis and treatment of osteoporosis accessible to all at
risk. There is now sufficient evidence to develop action plans. The
challenge is to stimulate young audience and to conduct effective
education programs to increase general awareness of the problem.
Public awareness programs regarding prevention, diagnosis and man-
agement of osteoporosis and fragility fractures should be a priority
strategy.
As patients with osteoporosis-related fractures are at higher risk of
subsequent re-fractures multiple programs have studied the efficacy of
systems for the prevention of secondary fractures, often referred to as a
fracture liaison service (FLS). Specifically, the FLS is a coordinated care
model of multiple providers who help guide the patient through os-
teoporosis management after a fragility fracture to help prevent future
fractures. Keeping in mind its efficiency and cost effectiveness Fracture
Liaison Services and development of national database is also dire need
of time.
4.1. Recommendations
1) It is recommended to cater the rampant Vitamin D Deficiency and
calcium intake in Pakistan through promotion of life style mod-
ification strategies and implementing food fortification policy.
2) Awareness campaigns at community level advocating role of phy-
sical activity in promoting bone health to create mindfulness about
attaining the peak bone mass disease and its implications are
needed.
3) Promoting osteoporosis training through medical education
Table 4
Prevalence of vitamin D deficiency in Pakistani population residing in different geographical areas.
Authors (ref) Year Place of study Study population Sample size Vitamin D deficiency %
Khan [50] 2012 Karachi Premenopausal women from community 305 90.5
Dar [49] 2012 Karachi Premenopausal healthy women 200 82
Hossain [57] 2011 Karachi Women in labor 75 89
Mansoor [58] 2010 Karachi Apparently healthy adults 123 90%
Zuberi [59] 2008 Karachi, Ambulatory care adult patients 119 92% (female: male ratio of 5:1)
Masud [60] 2007 Lahore Pre-menopausal women 195 81%
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curriculum to physicians should be initiated.
4) Screening for high risk individuals, provision of adequate diagnostic
facilities for DXA scanning for effective management and prompt
diagnosis at low cost should be targeted.
5) Coordinated care model of fracture liaison service (FLS) should be
promoted at Institutional level for prevention of secondary fracture
and appropriate follow-ups.
6) At national level, osteoporosis should be included in the national
action plan for the non-communicable diseases. So efforts to pro-
mote development of regional and national data base for fracture
can be initiated.
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